Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.64 |
| ▸ | THRB | P10828 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | PKM | P14618 | 8/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18184455 | 0.85 | TP53 (0.67) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL16032121 | 0.84 | TP53 (0.66) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL18184511 | 0.83 | TP53 (0.64) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL20364522 | 0.82 | TP53 (0.63) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL2953764 | 0.80 | MMP12 (0.64) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL25010388 | 0.79 | TP53 (0.71) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL20703688 | 0.78 | ALDH1A1 (0.60) | TP53THRBMAPTPKMPOLB | |
| SCHEMBL25010896 | 0.77 | PKM (0.79) | TP53THRBPKMPOLBLMNA | |
| SCHEMBL25010395 | 0.77 | TP53 (1.00) | TP53THRBPKMPOLBLMNA | |
| SCHEMBL25010953 | 0.76 | PKM (1.00) | TP53THRBMAPTPKMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | TP53 1736/4885THRB 594/4885MAPT 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.